Immune Thrombocytopenia (ITP) Market

The immune thrombocytopenia (ITP) market has been comprehensively analyzed in IMARC's new report titled "Immune Thrombocytopenia (ITP) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Immune thrombocytopenia (ITP) is a hematological disorder characterized by a decrease in the number of platelets in the blood, which are essential for normal blood clotting. In this condition, the immune system mistakenly attacks and destroys platelets, leading to easy or excessive bruising and bleeding. Individuals suffering from ITP often exhibit symptoms, such as superficial bleeding into the skin appearing as a rash of pinpoint-sized reddish-purple spots (petechiae), usually on the lower legs, bleeding from the gums or nose, blood in urine or stools, and unusually heavy menstrual flows. The diagnosis of the ailment involves a thorough medical history and physical examination, along with blood tests to count platelet levels. In some cases, additional tests such as bone marrow examination might be performed to rule out various other conditions.

The increasing prevalence of abnormal immune response, causing the body's defense system to mistakenly identify platelets as foreign invaders and produce antibodies to attack them, is primarily driving the immune thrombocytopenia (ITP) market. In addition to this, the inflating utilization of corticosteroids, such as prednisone, which help in boosting the platelet count by reducing the immune system's activity, is creating a positive outlook for the market. Moreover, the widespread adoption of thrombopoietin receptor agonists, like romiplostim and eltrombopag, since they can stimulate the production of platelets, is also bolstering the market growth. These medications help in maintaining a stable platelet count, thus reducing the risk of severe bleeding. Apart from this, the escalating application of splenectomy that involves the removal of the spleen, which is often responsible for the destruction of platelets in ITP patients, is acting as another significant growth-inducing factor. Additionally, the advancements in gene therapy and stem cell research, offering new insights into the underlying mechanisms of the disease and potential curative approaches, are augmenting the market growth. Besides this, the emerging popularity of rituximab, an antibody therapy that targets specific immune cells to reduce the immune system's attack on platelets, is expected to drive the immune thrombocytopenia (ITP) market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the immune thrombocytopenia (ITP) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for immune thrombocytopenia (ITP) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the immune thrombocytopenia (ITP) market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the immune thrombocytopenia (ITP) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the immune thrombocytopenia (ITP) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current immune thrombocytopenia (ITP) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report

Key Questions Answered in this Report

Market Insights

• How has the immune thrombocytopenia (ITP) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the immune thrombocytopenia (ITP) market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the immune thrombocytopenia (ITP) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of immune thrombocytopenia (ITP) across the seven major markets?
• What is the number of prevalent cases 2018-2034) of immune thrombocytopenia (ITP) by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of immune thrombocytopenia (ITP) by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with immune thrombocytopenia (ITP) across the seven major markets?
• What is the size of the immune thrombocytopenia (ITP) patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of immune thrombocytopenia (ITP)?
• What will be the growth rate of patients across the seven major markets?
   

Immune Thrombocytopenia (ITP): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for immune thrombocytopenia (ITP) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the immune thrombocytopenia (ITP) market?
• What are the key regulatory events related to the immune thrombocytopenia (ITP) market?
• What is the structure of clinical trial landscape by status related to the immune thrombocytopenia (ITP) market?
• What is the structure of clinical trial landscape by phase related to the immune thrombocytopenia (ITP) market?
• What is the structure of clinical trial landscape by route of administration related to the immune thrombocytopenia (ITP) market?